drug company, which is working on highly-targeted therapies, says Roche will help develop and commercialize the drug camonsertib.for the treatment of tumors.
Repare says under the terms of the licence and collaboration agreement, it will receive a US$125 million upfront payment, and is “eligible to receive up to US$1.2 billion in potential clinical, regulatory, commercial and sales milestones.”
Resumimos esta notícia para que você possa lê-la rapidamente. Se você se interessou pela notícia, pode ler o texto completo aqui. Consulte Mais informação: